NCT05184530

In-hospital Initiation of PCSK9 Inhibitor in Patients With Acute Myocardial Infarction

In-hospital Initiation of PCSK9 Inhibitor and Short-term Lipid Profile Alteration, as Well as In-hospital Mortality and Readmission Rate in Patients With Acute Myocardial Infarction

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 7,556 (actual)
• Sponsor: First Affiliated Hospital Xi'an Jiaotong University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to improve cardiovascular outcomes when added to conventional statin therapy. This study aims to investigate the efficacy and safety of in-hospital initiation of PCSK9 inhibitor among patients with acute myocardial infarction(AMI) based on real-world experience. A total of 7556 AMI patients from the biobank database between January 2016 and December 2020 were screened for eligibility. After excluding those without revascularization or Statin based therapy, the remaining 5802 Statin users, 801 Statin plus Ezetimibe users and 170 Statin plus Evolocumab users (including 95 users without and 75 users with Ezetimibe), were selected for this study. Then, 1st and 3rd-month follow-up data were collected and analysed, including in-hospital mortality, readmission rate and lipid profiles

Conditions

• Coronary Disease

Interventions

Type	Name	Description
DRUG	Evolocumab 140 MG/ML	140 mg per two weeks, subcutaneous injection

Timeline

• Start date: 2016-01-01
• Primary completion: 2020-12-01
• Completion: 2021-12-01
• First posted: 2022-01-11
• Last updated: 2022-01-11